Cargando…

The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer

OBJECTIVE: Kirsten rat sarcoma viral oncogene homolog (KRAS) is an important driver gene of non‐small cell lung cancer (NSCLC). Despite a rapid progress achieved in the targeted therapy, chemotherapy remains the standard treatment option for patients with KRAS‐mutant NSCLC. This study aimed to asses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Hanxiao, Huang, Dingzhi, Lin, Gen, Yang, Xue, Zhuo, Minglei, Chi, Yujia, Zhai, Xiaoyu, Jia, Bo, Wang, Jingjing, Wang, Yuyan, Li, Jianjie, An, Tongtong, Wu, Meina, Wang, Ziping, Zhao, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554448/ https://www.ncbi.nlm.nih.gov/pubmed/35394121 http://dx.doi.org/10.1002/cam4.4739

Ejemplares similares

Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting
por: Li, Jianjie, et al.
Publicado: (2021)

A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database
por: Jia, Bo, et al.
Publicado: (2020)

Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I–IIIA non-small cell lung cancer patients
por: Jia, Bo, et al.
Publicado: (2021)

Nomogram to predict cause‐specific mortality in extensive‐stage small cell lung cancer: A competing risk analysis
por: Zhong, Jia, et al.
Publicado: (2019)

Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database
por: Zhuo, Minglei, et al.
Publicado: (2019)

Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis
por: Li, Jianjie, et al.
Publicado: (2020)

Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study
por: Yang, Xue, et al.
Publicado: (2021)

Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience
por: Wang, Lu, et al.
Publicado: (2020)

Survival comparison of right and left side non‐small cell lung cancer in stage I–IIIA patients: A Surveillance Epidemiology and End Results (SEER) analysis
por: Jia, Bo, et al.
Publicado: (2019)

Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma
por: Li, Junfeng, et al.
Publicado: (2023)

Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients
por: Wang, Yida, et al.
Publicado: (2021)

Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database
por: Wang, Yuyan, et al.
Publicado: (2020)

Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma
por: Zhong, Jia, et al.
Publicado: (2018)

Optimal first‐line treatment for advanced thymic carcinoma
por: Yang, Xue, et al.
Publicado: (2019)

放Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification
por: Jia, Bo, et al.
Publicado: (2021)

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
por: Jia, Bo, et al.
Publicado: (2020)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma
por: Wang, Shuhang, et al.
Publicado: (2020)

Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer
por: Lv, Chunxin, et al.
Publicado: (2018)

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung
por: Duan, Jianchun, et al.
Publicado: (2015)

Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung Within Lung Cancer Patients
por: Zhuo, Minglei, et al.
Publicado: (2020)

Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer
por: Bai, Hua, et al.
Publicado: (2013)

Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer
por: Yang, Xue, et al.
Publicado: (2016)

ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane‐based chemotherapy
por: Zhong, Jia, et al.
Publicado: (2019)

Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer
por: Wang, Shuhang, et al.
Publicado: (2013)

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
por: Wang, Zhijie, et al.
Publicado: (2014)

Characterization of Lung and Oral Microbiomes in Lung Cancer Patients Using Culturomics and 16S rRNA Gene Sequencing
por: Sun, Yifan, et al.
Publicado: (2023)

Significant Upregulation of HERV-K (HML-2) Transcription Levels in Human Lung Cancer and Cancer Cells
por: Yang, Caiqin, et al.
Publicado: (2022)

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer
por: Zhu, Jian, et al.
Publicado: (2012)

A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
por: Liu, Yanxia, et al.
Publicado: (2022)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer
por: Guo, Xiaoyu, et al.
Publicado: (2018)

Clinical outcomes of KRAS-mutant non-small cell lung cancer under untargeted therapeutic regimes in the real world: a retrospective observational study
por: Wang, Ming-Ming, et al.
Publicado: (2023)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations
por: Lei, Lei, et al.
Publicado: (2019)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nc0rndrikogiu1r31b2hbvdn52